InflaRx N.V. (IFRX) vs Immuneering Corporation (IMRX)

InflaRx N.V. and Immuneering Corporation are both Biotechnology companies. InflaRx N.V. and Immuneering Corporation are of similar size ($284.4M and $280.8M). InflaRx N.V. grew revenue faster over the last twelve months: −83.4% against −84.8%. Across the 13 metrics below, InflaRx N.V. leads on 7 and Immuneering Corporation on 6.

Valuation

Metric IFRX IMRX Biotechnology median
P/E n/m n/m 7.88
P/S 7,267.48 871.47 11.47
P/B 1.31 1.45 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1,130.56 398.60 10.73
Earnings yield (30.69%) (24.36%) (28.84%)
Free cash flow yield (12.29%) (20.63%) (23.03%)

Profitability

Metric IFRX IMRX Biotechnology median
Gross margin (26,762.42%) 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (38.71%) (52.15%) (57.72%)
Return on assets (32.75%) (47.31%) (49.22%)
Return on invested capital 0.00% (97.14%) 0.00%

Growth

Metric IFRX IMRX Biotechnology median
Revenue growth (TTM) (83.39%) (84.76%) 5.64%
EPS growth (last fiscal year) 9.41% 37.75% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IFRX IMRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 8.22 19.47 4.73
Net debt to EBITDA 0.97 2.94 0.96

Dividend

Metric IFRX IMRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric IFRX IMRX Biotechnology median
Market cap 284.42m 280.79m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack